Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Matern Fetal Neonatal Med ; 24(8): 1060-4, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21250913

ABSTRACT

OBJECTIVE: The primary outcome measure of this study was the ability of rHuEPOα therapy to reduce transfusion needs, whereas secondary outcome measures were NICU-LOS and ventilation need. METHODS: All babies with BW <1250 g and GA <30 were eligible. Thirty premature neonates were enrolled in the study (10 treated, 20 controls). rHuEPOα was administered as 300 IU/kg/dose 3 times/week subcutaneously. Iron, folic acid and Vitamin E supplementation were administered in both groups. Hematologic variables and blood sampling were recorded during the study. RESULTS: In rHuEPO group, only four (40%) premature infants required a transfusion, averaging 0.4 ±â€Š0.52 transfusions/pts. A total of 23 transfusions were administered to controls; 11 (55%) infants received one transfusion at least, 55% required multiple transfusions. The average number of transfusions/pts was statistically different (1.15  ±â€Š 1.46 vs. 0.4 ±â€Š0.52; p = 0.02), as the cumulative number of transfused patients (55% vs. 40%; p<0.001). NICU stay was not statistically different, whereas ventilation-free days were increased in EPO group (p<0.05). CONCLUSIONS: R-Hu-EPO treatment in first post-natal weeks markedly enhanced erythropoiesis in severely premature infants compared with matched controls, with a significant impact on transfusion needs. EPO group experienced also a reduction of ventilation time and, possibly, a decreased occurrence of clinical BPD.


Subject(s)
Anemia/drug therapy , Blood Transfusion/statistics & numerical data , Erythropoietin/therapeutic use , Hematinics/therapeutic use , Infant, Premature, Diseases/drug therapy , Respiration, Artificial/statistics & numerical data , Anemia/blood , Anemia/therapy , Case-Control Studies , Combined Modality Therapy , Drug Administration Schedule , Erythropoietin/administration & dosage , Folic Acid/administration & dosage , Folic Acid/therapeutic use , Hematinics/administration & dosage , Humans , Infant, Newborn , Infant, Premature , Infant, Premature, Diseases/blood , Infant, Premature, Diseases/therapy , Infant, Very Low Birth Weight , Intensive Care Units, Neonatal , Iron/administration & dosage , Iron/therapeutic use , Length of Stay/statistics & numerical data , Treatment Outcome
2.
Clin Chem ; 47(6): 1016-22, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11375286

ABSTRACT

BACKGROUND: There is a wide range of reported sensitivities and specificities for C-reactive protein (CRP) and interleukin-6 (IL-6) in the detection of early-onset neonatal infection. This prompted us to assess reference intervals for CRP and IL-6 during the 48-h period immediately after birth and to identify maternal and perinatal factors that may affect them. METHODS: CRP and IL-6 values were prospectively obtained for 148 healthy babies (113 term, 35 near-term) at birth and at 24 and 48 h of life, and from their mothers at delivery. RESULTS: Upper reference limits for CRP at each neonatal age were established. At birth, CRP was significantly lower than at 24 and 48 h of life. Rupture of membranes > or =18 h, perinatal distress, and gestational hypertension significantly affected the neonatal CRP dynamics, but at specific ages. There was no correlation between CRP concentrations in mothers and their offspring at birth. The IL-6 values observed in the delivering mothers and in their babies at all three neonatal ages were negatively associated with gestational age. In the immediate postnatal period, IL-6 dynamics for term babies were significantly different from those for near-term babies. Maternal IL-6 concentrations correlated with babies' IL-6 concentrations only for term deliveries. Apgar score had a significant effect on babies' IL-6 values at birth. CONCLUSIONS: The patterns of CRP and IL-6 responses in the healthy neonate should be taken into account to optimize their use in the diagnosis of early-onset neonatal sepsis.


Subject(s)
C-Reactive Protein/analysis , Infant, Newborn, Diseases/diagnosis , Interleukin-6/analysis , Adult , Confounding Factors, Epidemiologic , Female , Humans , Infant, Newborn , Infant, Newborn, Diseases/metabolism , Male , Perinatal Care , Postnatal Care , Pregnancy , Pregnancy Outcome , Prognosis
SELECTION OF CITATIONS
SEARCH DETAIL
...